Certolizumab pegol in the treatment of takayasu arteritis
Novikov P. I., Smitienko I. O., Sokolova M. V., Alibaz-Oner F., Kaymaz-Tahra S., Direskeneli H., Moiseev S. V.
Rheumatology (Oxford, England)
Vol.57, Issue12, P. 2101-2105
Опубликовано: 2018
Тип ресурса: Статья
DOI:10.1093/rheumatology/key197
Аннотация:
Objectives. Certolizumab pegol (CZP) is a PEGylated antigen-binding fragment-fragment of a humanized mAb neutralizing TNF. It lacks Fc-fragment and has a very low potential to cross the placenta. We aimed to report the efficacy and safety of CZP in a case series of patients with refractory Takayasu arteritis (TA). Methods. Ten females of reproductive age (1835 years) with TA were treated with CZP (at a dose of 400 mg at weeks 0, 2 and 4 and at 200 mg every 2 weeks thereafter) for a median of 10 months (range 328). Prior to CZP administration all patients received glucocorticoids and ± MTX, CYC, AZA, HCQ, LEF or MMF. Six patients were previously treated with other biological anti-cytokine drugs. The National Institutes of Health criteria and the Indian Takayasu Clinical Activity Score 2010 were used to define disease activity. Results. All patients rapidly responded to treatment with CZP and were able to taper prednisone and MTX doses. Treatment with CZP resulted in a significant decrea
Ключевые слова:
Certolizumab pegol; Takayasu arteritis; TNF inhibitors
acute phase protein; adalimumab; amoxicillin; antivirus agent; C reactive protein; certolizumab pegol; clavulanic acid; etanercept; fosfomycin; glucocorticoid; infliximab; methotrexate; prednisone; tocilizumab; antirheumatic agent; certolizumab pegol; glucocorticoid; methotrexate; prednisone; abscess; adult; antiviral therapy; aortic arch syndrome; arteritis; artery lesion; artery occlusion; Article; blood vessel wall; clinical article; community acquired pneumonia; computed tomographic angiography; disease activity; drug efficacy; drug safety; drug withdrawal; edema; female; follow up; herpes labialis; human; immunosuppressive treatment; infection; lactation; national health organization; nuclear magnetic resonance imaging; pregnancy; priority journal; protein blood level; psoriasis; relapse; remission; stenosis; systemic vasculitis; tonsillitis; treatment duration; urinary tract infection; vasculitis; adolescent; aortic arch syndrome; combination drug therapy; induction chemotherapy
Язык текста: Английский
ISSN: 1462-0332
Novikov P. I. Pavel Igorevich 1982-
Smitienko I. O.
Sokolova M. V.
Alibaz-Oner F.
Kaymaz-Tahra S.
Direskeneli H.
Moiseev S. V. Sergej Valentinovich 1960-
Новиков П. И. Павел Игоревич 1982-
Смитиенко И. О.
Соколова М. В.
Алибаз-Онер Ф.
Каймаз-Тахра С.
Дирескенели Х.
Моисеев С. В. Сергей Валентинович 1960-
Certolizumab pegol in the treatment of takayasu arteritis
Текст визуальный непосредственный
Rheumatology (Oxford, England)
Oxford University Press
Vol.57, Issue12 P. 2101-2105
2018
Статья
Certolizumab pegol Takayasu arteritis TNF inhibitors
acute phase protein adalimumab amoxicillin antivirus agent C reactive protein certolizumab pegol clavulanic acid etanercept fosfomycin glucocorticoid infliximab methotrexate prednisone tocilizumab antirheumatic agent certolizumab pegol glucocorticoid methotrexate prednisone abscess adult antiviral therapy aortic arch syndrome arteritis artery lesion artery occlusion Article blood vessel wall clinical article community acquired pneumonia computed tomographic angiography disease activity drug efficacy drug safety drug withdrawal edema female follow up herpes labialis human immunosuppressive treatment infection lactation national health organization nuclear magnetic resonance imaging pregnancy priority journal protein blood level psoriasis relapse remission stenosis systemic vasculitis tonsillitis treatment duration urinary tract infection vasculitis adolescent aortic arch syndrome combination drug therapy induction chemotherapy
Objectives. Certolizumab pegol (CZP) is a PEGylated antigen-binding fragment-fragment of a humanized mAb neutralizing TNF. It lacks Fc-fragment and has a very low potential to cross the placenta. We aimed to report the efficacy and safety of CZP in a case series of patients with refractory Takayasu arteritis (TA). Methods. Ten females of reproductive age (1835 years) with TA were treated with CZP (at a dose of 400 mg at weeks 0, 2 and 4 and at 200 mg every 2 weeks thereafter) for a median of 10 months (range 328). Prior to CZP administration all patients received glucocorticoids and ± MTX, CYC, AZA, HCQ, LEF or MMF. Six patients were previously treated with other biological anti-cytokine drugs. The National Institutes of Health criteria and the Indian Takayasu Clinical Activity Score 2010 were used to define disease activity. Results. All patients rapidly responded to treatment with CZP and were able to taper prednisone and MTX doses. Treatment with CZP resulted in a significant decrea